StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
002622.SZ$2.59+3.95%
Fair $2.59+0.0%

002622.SZ

Whole Shine Medical Technology Co., Ltd.

Industrials / Specialty Industrial MachineryShenzhen

$2.59

+0.10 (+3.95%)

Fairly Valued+0.0%Fair Value $2.59Fund rank 25/100 · Data gapFallback financials|
SA 11/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $78.6M · quality 42.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 44/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

11/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -44.1%, below the 5% threshold
Thesis & Journal · 002622.SZLocal privado en este navegador · Whole Shine Medical Technology Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.2B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-44.1%

↓

Gross Margin

44.6%

↑

Debt/Equity

1.66

↑
52-Week Range$3
$2$5

TradingView lightweight chart

002622.SZ price, volumen y niveles de valoración

Último $2.630Periodo -43.6%
Fair value: $2.590

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+12.0%

FCF CAGR

+74.8%

FCF margin

6.3%

FCF / Net income

-0.37x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $702.9M · net income $-119.4M · FCF $44.1M

2022-FY → 2025-FY

Gross margin

44.6%+3.1% pts

Operating margin

-2.6%+10.3% pts

Net margin

-17.0%+34.3% pts

FCF margin

6.3%+4.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$702.9M$702.9M$861.6M$756.7M$500.7M
Net Income$-119.4M$-119.4M$-37.7M$-94.4M$-256.8M
EBITDA$-29.8M$-29.8M$97.3M$54.2M$-164.0M
EPS-0.14-0.14-0.04-0.11-0.31
Gross Margin44.6%44.6%48.3%50.9%41.5%
Operating Margin-2.6%-2.6%6.5%10.1%-12.9%
Net Margin-17.0%-17.0%-4.4%-12.5%-51.3%
Balance Sheet
Debt/Equity1.661.661.201.160.88
Current Ratio0.290.29———
Cash Flow
Free Cash Flow$44.1M$44.1M$78.6M$103.4M$8.3M
Returns
ROE-44.1%-44.1%-9.5%-21.8%-44.9%
Valuation
EV/EBITDA——25.2258.33—
P/B8.038.035.346.485.53
Growth & Yield
Revenue Growth-18.4%-18.4%13.9%51.1%—
EPS Growth-216.7%-216.7%60.0%63.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -4.4%

Total return

-4.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.04 → -0.14

Residual

-4.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-4.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.